Decitabine

Evidence Level: L5

Predicted Indications: 1

Decitabine

Pharmacist Assessment Report

Decitabine: DNA hypomethylating agent → refractory cytopenia of childhood (refractory cytopenia of childhood)

One-Sentence Summary

Decitabine is a hypomethylating agent used in myeloid malignancies. The TxGNN model predicts it may be useful for refractory cytopenia of childhood, but no registered clinical trials were found, and the 2 publications available are a single-center cohort and a case report in paediatric myelodysplastic syndrome (MDS), a broader group that includes this condition.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	refractory cytopenia of childhood (refractory cytopenia of childhood)
TxGNN Prediction Score	0.9903
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 2 of 2)
Number of DINs	2 (marketed: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data are not available in the data compiled for this report. Decitabine is generally known as a DNA methyltransferase inhibitor (hypomethylating agent), a class used in myeloid malignancies including acute myeloid leukaemia and myelodysplastic syndromes.

Refractory cytopenia of childhood is the most common paediatric MDS subtype. Aberrant DNA methylation and clonal myeloid dysplasia are shared biology in MDS, which gives a plausible mechanistic link. This rationale rests on the general pharmacology of the drug class, not on mechanism data supplied here.

The high TxGNN score (0.9903) is a computational output only and is not clinical evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35624441	2022	Cohort	BMC Pediatrics	Single-center 10-year experience of decitabine plus a minimally myelosuppressive regimen as a bridge to allogeneic stem cell transplantation in children with MDS
42125547	2026	Case report	Experimental and Therapeutic Medicine	Decitabine monotherapy in an 8-year-old with paediatric MDS (most commonly presenting as refractory cytopenia of childhood) who was ineligible for transplantation or immunosuppressive therapy

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02484811	DEMYLOCAN	Not recorded	Not recorded
02501600	INQOVI	Not recorded	Not recorded

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (nucleoside analogue, hypomethylating agent)
Myelosuppression Risk	High (neutropenia and thrombocytopenia are expected with this class)
Emetogenicity Classification	Low to moderate
Monitoring Items	CBC with differential, liver and renal function
Handling Protection	Follow cytotoxic drug handling regulations; please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions: 100 interactions were found in the interaction data. Examples at Major level include deferiprone, samarium (153Sm) lexidronam, adalimumab and baricitinib. Moderate-level examples include mercaptopurine, zidovudine, ganciclovir, gemcitabine, azathioprine and aldesleukin.

For other safety information, please refer to the package insert.

Conclusion and Next Steps

Decision: Hold

Rationale: The only evidence is one single-center cohort and one case report in paediatric MDS in general, with no registered trials and no study that directly addresses refractory cytopenia of childhood. The very high model score is not clinical evidence.

To proceed, the following is needed:

Studies or trials that directly evaluate decitabine in refractory cytopenia of childhood
Mechanism-of-action data
Package insert warnings and contraindications from Health Canada
A safety plan for paediatric patients, including myelosuppression monitoring
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.